Multiple Sclerosis Clinical Trial
— PT-MSOfficial title:
Proximal Resistance Training to Improve Walking Capacity and Physical Activity in People With Multiple Sclerosis: A Feasibility Study
Verified date | October 2023 |
Source | University of Colorado, Denver |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to pilot a 10-week resistance and functional movement intervention targeting proximal muscles in 40 people with MS. The investigators will assess implementation feasibility (recruitment, fidelity, retention, satisfaction), collect pilot data for key walking function outcomes, and examine movement-pattern and activity behavior mechanisms. Walking function will be measured by walking capacity (6-Minute Walk Test - 6MWT) and PA quantity (average steps/ day over 10 days). Movement-pattern mechanisms will be measured using 3D motion capture analysis (pelvis and trunk kinematics). Activity behavior mechanisms will be measured by patient-reported outcome questionnaires (perception of walking ability, self-efficacy, and readiness to change).
Status | Completed |
Enrollment | 34 |
Est. completion date | October 31, 2022 |
Est. primary completion date | October 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility | Inclusion Criteria. - 18-64 years old - Neurologist-confirmed diagnosis of MS - Able to walk at least 100 meters without an assistive device - Expanded Disability Status Scale - EDSS < 6 - Have their own tablet/phone/computer capable of video calls/Zoom meetings. Exclusion Criteria. - Other conditions limiting their ability to exercise or walk - Unsafe to exercise as determined by a neurologist or physical therapist - Currently undergoing physical therapy - Unable to provide consent or follow simple directions - Have an MS-related exacerbation or changes to their disease-modifying drug therapy in the month prior to enrollment - A 25 foot walk test time of > 4.5 seconds |
Country | Name | City | State |
---|---|---|---|
United States | University of Colorado | Aurora | Colorado |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Patient-Specific Functional Scale | Participant identifies 3 activities that the participant is unable to do, or is difficult for the participant to do and rates them on a 10-point scale, with higher scores indicating greater ability to perform activity. | Baseline and end of 10 week intervention period. | |
Other | Change in hip abduction strength | Hip abduction strength will be measured in kg using hand-held dynamometry. | Baseline, end of 10 week intervention period, 22 week follow-up. | |
Other | Change in lateral trunk flexion strength | Lateral trunk flexion strength will be measured in kg using hand-held dynamometry. | Baseline, end of 10 week intervention period, 22 week follow-up. | |
Other | Change in lateral trunk flexion endurance | Trunk flexion endurance as measured by a clinical trunk curl-up test which counts the number of trunk curls a participant can perform in 1 minute. | Baseline, end of 10 week intervention period, 22 week follow-up. | |
Other | Expanding Disability Status Scale | Neurological exam used to assess disability in people with multiple sclerosis. Scores range from 0 to 6 with higher scores indicating more disability. | Baseline | |
Other | 25 Foot Walk Test | Amount of time in seconds it takes for participant to walk 25 feet as quickly and safely as possible. | Baseline and after the 10 week intervention period. | |
Primary | Change in 6-minute walk test | The 6MWT assesses walking endurance via the maximal distance an individual is able to walk in 6 minutes, reported in meters | Baseline, end of 10 week intervention period, 22 week follow-up. | |
Secondary | Change in average daily step count | Step count will be measured by waist-mounted ActiGraph accelerometer-based activity monitors | Baseline, end of 10 week intervention period, 22 week follow-up. | |
Secondary | Change in movement patterns | Mechanisms of movement patterns will be measured by 3-dimensional motion capture analysis during self-selected walking speed and during a 30 second chair raise test. | Baseline, end of 10 week intervention period, 22 week follow-up. | |
Secondary | Change in Multiple Sclerosis Walking Scale-12 | A 12 questions assessment of self-reported walking mobility in people with multiple sclerosis. Scores range from 0 to 100 with higher scores indicating better mobility. | Baseline, end of 10 week intervention period, 22 week follow-up. | |
Secondary | Change in Multiple Sclerosis Self-Efficacy Score | An 18 item assessment of measures of self-efficacy in multiple sclerosis including a function component and a control component. Total score is reported on a 10-100 point scale with higher scores indicating greater certainty in ones ability to manage multiple sclerosis symptoms. | Baseline, end of 10 week intervention period, 22 week follow-up. | |
Secondary | Change in Exercise Self-Efficacy Scale | A 9 item questionnaire that assesses perceptions about ability to participate in at least 20 minutes of moderate physical activity 3x per week. Scores range from 0 to 90 points with higher scores indicating more confidence to exercise in different circumstances. | Baseline, end of 10 week intervention period, 22 week follow-up. | |
Secondary | Change in Exercise Stages of Change category | A 4 item measure to assess readiness to participate in exercise and activity. Depending on the answers to the yes/no questions, results are categorized as "pre-contemplation", "contemplation", "preparation", "action", and "maintenance". | Baseline, end of 10 week intervention period, 22 week follow-up. | |
Secondary | Change in Modified Fatigue Impact Scale | The standard measure of patient-reported limitations due to fatigue in people with MS. Scores range from 0 to 84 with higher scores indicating higher impact of fatigue on daily activities. | Baseline, end of 10 week intervention period, 22 week follow-up. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |